Tango Therapeutics, Inc. (TNGX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US87583X1090
Tango Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 62.38 m USD |
| Operating income | -111.29 m USD |
| EBIT | -101.59 m USD |
| Net income | -101.59 m USD |
| Diluted EPS – continuing operations | -0.87 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
More stocks
- Baytex Energy Corp (BTE.TO)
- Santen Pharmaceutical Co Ltd (4536.T)
- Huber+Suhner AG (HUBN.SW)
- Koei Tecmo Holdings Co Ltd (3635.T)
- Bellway PLC (BWY.L)
- GEO GROUP INC (GEO)
- Ermenegildo Zegna NV (ZGN)
- KT Corporation (KT)
- HICL Infrastructure PLC (HICL.L)
- Jiangsu Hoperun Software Co Ltd (300339.SZ)
- T&S Communications Co Ltd (300570.SZ)
- Sacyr SA (SCYR.MC)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.